SearchesSearch termsResults
1(lapatinib or tykerb or tyverb or lapatinib ditosylate).af.2435
2(trastuzumab or herceptin).af.10,741
3(letrozole or femara or anastrozole or arimidex or exemestane or aromasin).af.5962
4Aromatase Inhibitors.mp. or exp aromatase inhibitor/11,914
51 or 211,728
63 or 411,959
75 and 61472
8(breast$adj5 (neoplasm$or cancer$or tumo?r$or carcinoma$or adenocarcinoma$or sarcoma$or dcis or ductal or infiltrat$or intraductal$or lobular or medullary)).mp.195,921
9exp breast cancer/167,175
108 or 9197,019
117 and 101378
12limit 11 to (human and english language)1195

From: Appendix 1, Literature search strategies

Cover of Lapatinib and Trastuzumab in Combination with an Aromatase Inhibitor for the First-Line Treatment of Metastatic Hormone Receptor-Positive Breast Cancer which Over-Expresses Human Epidermal Growth Factor 2 (HER2): A Systematic Review and Economic Analysis
Lapatinib and Trastuzumab in Combination with an Aromatase Inhibitor for the First-Line Treatment of Metastatic Hormone Receptor-Positive Breast Cancer which Over-Expresses Human Epidermal Growth Factor 2 (HER2): A Systematic Review and Economic Analysis.
Health Technology Assessment, No. 15.42.
Fleeman N, Bagust A, Boland A, et al.
Southampton (UK): NIHR Journals Library; 2011 Dec.
© 2011, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.